Asia-Pacific CRO Novotech signs MOU with Taiwanese hospital

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/utah778)
(Image: Getty/utah778)
Novotech has signed a Memorandum of Understanding (MOU) with the China Medical University Hospital (CMUH) in Taiwan.

The Australia-headquartered contract research organization (CRO) Novotech have five MOUs with major health providers.

Per its agreement with the CMUH, the hospital will provide Novotech’s team with “professional and medical clinical trial advice,”​ including feasibility, principal investigator selection, and patient recruitment support.

Conversely, Novotech will promote CMUH’s clinical research capabilities, specifically its Phase I unit.

The CMUH has 2,054 beds and a dedicated Clinical Trials Center (CTC), which joined the "International Clinical Trials Center Network" (ICN) in 2016.

The ICN includes Zurich University, Harvard University, Cambridge University, and the University of Hong Kong.

Related topics: Clinical Development, Phase I-II

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more